Technology | Intravascular Imaging

Pie Medical Imaging announced the release of CAAS IntraVascular 2.0, the dedicated software for analysis of intravascular ultrasound (IVUS), near-infrared spectroscopy (NIRS)-IVUS and optical coherence tomography (OCT) datasets. This new release contains an optimized OCT analysis and the in-depth analysis of NIRS-IVUS datasets. Data can be imported easily from the console or picture archiving and communication system (PACS) into the study list, which provides a clear overview of your data. CAAS IntraVascular has U.S. Food and Drug Administration (FDA) 510(k) clearance for both IVUS and OCT.

Home August 03, 2015
Home
European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic
Feature | Stents

According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents accounted for a significant portion of the European markets for interventional cardiology devices in 2014. The advent of drug-eluting stents has driven the interventional cardiology market beyond expectations, as these devices have managed to increase the size of the market by virtue of their relatively high average selling price (ASP). New developments in drug-eluting stents such as biodegradable materials are expected to keep the market competitive despite safety concerns regarding late stent thrombosis.

Home July 31, 2015
Home
News | Cardiovascular Ultrasound

The American Society of Echocardiography (ASE) released a new document describing various imaging strategies for diagnosing a “hole in the heart,” one of the most common types of congenital heart defects. The document, Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions, describes the various defects, the modalities used to evaluate them, and clearly lays out strategies for optimal imaging.

Home July 31, 2015
Home
News | Ultrasound Imaging

After a tornado decimated the hospital only four years ago, Mercy Hospital Joplin in Joplin, Missouri, reopened its doors in March with a new, 900,000-square-foot facility with state-of-the-art equipment. Part of the acquisition by Mercy Hospital Joplin, formerly St. John’s Regional Medical Center, included eight Aplio 300 Platinum ultrasound systems from Toshiba America Medical Systems Inc.

Home July 30, 2015
Home
News | Radiopharmaceuticals and Tracers

Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept, a Manocept platform product, to localize in high-risk atherosclerotic plaques. The study — funded through a $321,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), National Institute of Health (NIH) — will be conducted with Massachusetts General Hospital (MGH) and Harvard Medical School.

Home July 30, 2015
Home
Technology | Robotic Systems

The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.

Home July 29, 2015
Home
News | Stem Cell Therapies

A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus infusion affects end-stage heart failure patients is showing promising results. The method involves giving the cells backwards (retrograde) through the heart through the main vein (the coronary sinus).

Home July 29, 2015
Home
News | Contrast Media

Guerbet announced that it has entered into a definitive agreement under which it will acquire Mallinckrodt's contrast media and delivery systems business ("CMDS").

Home July 29, 2015
Home
News | Cardiovascular Ultrasound

Epsilon Imaging Inc. announced that several studies were presented at the American Society of Echocardiography (ASE) 2015 conference, June 13-16, on its EchoInsight automated measurement suite for improved analysis and interpretation in echo.

Home July 29, 2015
Home
Itrevia 7 HF-T QP, Biotronik, CRT-D, first U.S. implantations, CLS algorithm
Feature | Cardiac Resynchronization Therapy Devices (CRT)

Biotronik announced the first patients have been successfully implanted with Itrevia HF-T QP cardiac resynchronization defibrillator (CRT-D) devices. Itrevia HF-T QP includes the Closed Loop Stimulation (CLS) algorithm, capable of appropriately adapting heart rate in response to physiological demands independent of body movements or respiratory rate.

Home July 28, 2015
Home
Feature | Heart Valve Technology

Boston Scientific announced CE Mark and U.S. Food and Drug Administration (FDA) clearance for the Safari2 Pre-Shaped Guidewire. Safari2 is an enhanced version of the Safari Guidewire, intended to facilitate the introduction and placement of interventional devices within the heart, including those used with transcatheter aortic valve implantation or replacement procedures (TAVI/R). The Safari2 Guidewire is compatible for use with all TAVI/R devices.

Home July 28, 2015
Home
Technology | Atherectomy Devices

Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its new ViperWire Advance Peripheral Guide Wire with Flex Tip for their peripheral orbital atherectomy systems (OAS). The new guide wire provides physicians with improved flexibility, navigation and ease-of-use, particularly in hard-to-reach, tortuous vessels when treating arterial calcium associated with peripheral artery disease (PAD).

Home July 22, 2015
Home
News | Heart Failure

Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated with a cardiac resynchronization therapy device (CRT) equipped with an algorithm to automatically deliver and adjust therapy, according to a recent study in JACC: Heart Failure. The study compared these patients to those receiving the standard CRT optimized with echocardiography.

Home July 22, 2015
Home
News | Heart Valve Technology

Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in April to broaden its SALUS Trial. The expansion includes the addition of high-risk patients and randomization against a commercial device, the Medtronic CoreValve.

Home July 22, 2015
Home
News | Cath Lab

The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company in its bivalirudin (Angiomax) patent litigation with Hospira Inc.

Home July 22, 2015
Home
Subscribe Now